Tackling antimicrobial resistance in neonatal sepsis. by Folgori, L et al.
Comment
www.thelancet.com/lancetgh   Vol 5   November 2017 e1066
Tackling antimicrobial resistance in neonatal sepsis 
The reduction of maternal and child mortality, which has 
halved worldwide in the past two decades, is considered 
one of the greatest successes of the Millennium 
Development Goals programme.1 However, the number 
of neonatal deaths has remained unacceptably high, 
with an estimated 2·9 million deaths every year (44% of 
all deaths in children younger than 5 years, worldwide).2 
In 2012, the most common causes of neonatal death 
globally were preterm-birth complications, intrapartum-
related conditions, and infections. 
Globally, infections cause nearly a quarter 
(23%) of all neonatal deaths, with neonatal sepsis 
accounting for 15% of these deaths.1 Severe bacterial 
infections in neonates account for about 3% of all 
disability-adjusted life-years.3 Prompt diagnosis 
and appropriate treatment are crucially important 
in reducing mortality. However, the worldwide 
spread of antimicrobial resis tance represents a major 
challenge, with nearly half of the pathogens that 
cause severe neonatal bacterial infections reported to 
be resistant to the first-line (ampicillin or penicillin, 
and gentamicin) and second-line (third-generation 
cephalosporins) WHO-recommended treatments.4 In 
2016, the first estimate of neonatal deaths attributable 
Panel: Treatments expected to be developed as part of the NeoAMR Project
Regimen 1
Indication
Empirical treatment of neonatal sepsis, including meningitis, in 
premature and term infants, early and late onset infection 
Patient population
Neonates with possible severe bacterial infections in settings 
with a high prevalence of resistance to first-line WHO 
recommended treatment 
Route of administration
Intravenous, 30 min infusions 
Dosing schedule
Once or twice daily 
Efficacy
Comparable to amoxicillin-gentamicin or ceftriaxone-
gentamicin in claimed indication, with activity against 
pathogens that are resistant to amoxicillin-gentamicin or 
ceftriaxone-gentamicin
Treatment duration
5–10 days 
Safety and tolerability
Low propensity for resistance development, large therapeutic 
window, minimal hepatotoxicity, nephrotoxicity, and central 
nervous system toxicity, no prolongation of the QT interval 
Drug interactions
Similar to the first-line WHO empirical treatments 
Key countries
South America, Asia, and Africa 
Pharmacoeconomics
Reduction of intensive care unit and length of hospital stay 
(modelling)
Current standard of care
Amoxicillin-gentamicin or ceftriaxone-gentamicin, as per WHO 
recommendations
Regimen 2
Indication
Neonatal sepsis and meningitis, when multidrug-resistance—
specifically carbapenem-resistant, Gram-negative pathogens—
has been shown, including Klebsiella pneumoniae, Pseudomonas 
aeruginosa, or Acinetobacter spp 
Patient population
Neonates admitted to hospital with severe infections, failure on 
optimal current treatment, and positive microbiological culture 
Route of administration
Intravenous, 30 min infusion
Dosing schedule
Once or twice daily
Efficacy
Similar to existing options in claimed indication and activity in 
pathogens resistant to carbapenems 
Treatment duration
5–10 days 
Safety and tolerability
Low propensity for resistance development, large therapeutic 
window, minimal hepatotoxicity, nephrotoxicity, and central 
nervous system toxicity, no prolongation of the QT interval 
Drug interactions
Similar to standard of care 
Key countries
South America, Asia, and Africa 
Pharmacoeconomics
Reduction of intensive care unit and length of hospital stay 
(modelling)
Current standard of care
Colistin monotherapy
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to antimicrobial resistance was published,5 with 
multidrug-resistant pathogens approximated to 
account for 30% of all global neonatal sepsis mortality.5 
Multidrug-resistant pathogens are a challenge in 
high-income countries, but are even more so in low-
income and middle-income countries because of 
insufficient access to antibiotics, higher burden of 
infectious diseases, weak health-care systems, and 
resources limitations. Nowadays, multidrug-resistance 
Gram-negative bacteria are of the greatest concern 
in neonates because few therapeutic options are 
available.6 Extended-spectrum β-lactamase (ESBL)-
producing Enterobacteriaceae and carbapenem-
resistant Enterobacteriaceae (CRE) are responsible 
for an increasing number of outbreaks of health-
care-associated infection in neonatal intensive care 
units (NICUs), and are associated with substantial 
morbidity and mortality. The emergence and spread 
of ESBL and CRE among NICUs has inevitably led to 
the reintroduction of old antibiotics, such as colistin 
and fosfomycin, often with minimal information 
distributed on drug safety and optimal dosing. 
Few data are available to support an optimal 
treatment of multidrug-resistant infections, even in 
adults, with very few randomised trials and most data 
coming from retrospective observational studies. Data6,7 
on the number of robust clinical studies assessing old 
or new antibiotics involving neonates indicate that a 
very small number of trials are being conducted—ie, 
globally less than ten antibiotic trials involving preterm 
infants have been conducted. To address this need for 
additional data, the Global Antibiotic Research and 
Development Partnership (GARDP), a joint initiative of 
WHO and the Drugs for Neglected Diseases initiative 
(DNDi) in support of the Global Action Plan for 
Antimicrobial Resistance, established a new priority-
setting framework, with the mission to develop 
new antibiotic regimens to address drug-resistant 
infections, promote their responsible use, and make 
them accessible for all populations in need.8 As part of 
this initiative, the GARDP has launched a neonatal sepsis 
programme, which will include the NeoAMR Project (to 
be launched on Nov 8, 2017). This project will aim to 
develop new, globally applicable, empirical antibiotic 
regimens and strategies for the treatment of neonatal 
sepsis that can be adapted to settings with varying 
prevalence of multidrug-resistant pathogens. 
The specific aim of the NeoAMR Project is to develop 
two treatments targeting two specific areas of need. 
First, an empirical regimen that serves as an alternative 
to amoxicillin and gentamicin in areas where a high 
prevalence of ESBL Gram-negative bacteria pathogens 
are suspected, and second, a treatment regimen to 
be used in situations when carbapenem-resistant 
Gram-negative bacteria have been shown. The panel 
summarises the main characteristics expected of these 
treatments. 
The lead candidate for the first regimen consists of 
a combination of fosfomycin and amikacin since this 
combination would ensure adequate central nervous 
system penetration (which is essential considering 
the high incidence of meningitis in neonates with 
sepsis), low resistance development, good safety 
profile, and broad spectrum of activity. For the second 
regimen, a hollow fibre infection model has been 
developed9 to identify suitable candidate combinations. 
These regimens could consist of an optimally dosed 
polymyxin-based combination, or other antibiotics 
that are in development or recently registered for use 
in adults that could prevent the emergence of drug 
resistance while resulting in maximal antibacterial 
activity, or a combination of these drugs. 
The global shortage of antibiotics that are avail-
able for use in neonates is of increasing concern, 
particularly given the increase of antimicrobial 
resistance and the marked paucity of research in 
this vulnerable population. Neonates should be 
more highly prioritised in research and development 
globally, including in the development of enhanced 
diagnostics that are practical  for use in low-income 
and middle-income countries, combined with the 
provision of novel evidence-based treatment options 
that can be available worldwide. The NeoAMR Project 
will provide the general framework for the design 
and implementation of large-scale neonatal sepsis 
trials across different geographical settings. It will 
also become the platform for future initiatives in this 
area, including monitoring the ongoing effect of these 
initiatives, and will seek to ensure that its outcomes 
are translated into appropriate policies and guidelines 
at both national and global levels.
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